CA3032654A1 - Composition for injection which can be used for treatment of heart diseases and contains fibroblasts, and method for producing fibroblast for therapy use - Google Patents
Composition for injection which can be used for treatment of heart diseases and contains fibroblasts, and method for producing fibroblast for therapy use Download PDFInfo
- Publication number
- CA3032654A1 CA3032654A1 CA3032654A CA3032654A CA3032654A1 CA 3032654 A1 CA3032654 A1 CA 3032654A1 CA 3032654 A CA3032654 A CA 3032654A CA 3032654 A CA3032654 A CA 3032654A CA 3032654 A1 CA3032654 A1 CA 3032654A1
- Authority
- CA
- Canada
- Prior art keywords
- fibroblasts
- cells
- cell
- positive
- cardiac
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/33—Fibroblasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Hospice & Palliative Care (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017-033624 | 2017-02-24 | ||
| JP2017033624 | 2017-02-24 | ||
| PCT/JP2018/006795 WO2018155651A1 (ja) | 2017-02-24 | 2018-02-23 | 線維芽細胞を含む心臓疾患を治療するための注射用組成物、及び治療用線維芽細胞の製造方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3032654A1 true CA3032654A1 (en) | 2018-08-30 |
Family
ID=63253929
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3032654A Pending CA3032654A1 (en) | 2017-02-24 | 2018-02-23 | Composition for injection which can be used for treatment of heart diseases and contains fibroblasts, and method for producing fibroblast for therapy use |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11096969B2 (OSRAM) |
| EP (1) | EP3476395B1 (OSRAM) |
| JP (2) | JP6618066B2 (OSRAM) |
| KR (1) | KR102407387B1 (OSRAM) |
| CN (1) | CN109890398B (OSRAM) |
| AU (1) | AU2018223739B2 (OSRAM) |
| CA (1) | CA3032654A1 (OSRAM) |
| DK (1) | DK3476395T3 (OSRAM) |
| ES (1) | ES2885080T3 (OSRAM) |
| IL (1) | IL267958B2 (OSRAM) |
| SG (1) | SG11201900810WA (OSRAM) |
| WO (1) | WO2018155651A1 (OSRAM) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL281081B (en) | 2018-08-29 | 2022-07-01 | Metcela Inc | A method to generate fibroblast and fibroblastic mass positive for g-csf |
| CN109589337B (zh) | 2018-12-29 | 2022-04-26 | 南京艾尔普再生医学科技有限公司 | 心肌细胞制剂及其制备方法和应用 |
| CN115210361B (zh) * | 2020-03-04 | 2024-12-10 | 淋巴奥格尼克斯有限公司 | 促红细胞生成素产生能力增强的成纤维细胞、制造方法以及医药组合物 |
| IL305069A (en) * | 2021-03-04 | 2023-10-01 | Metcela Inc | Fibroblast beta-factor promotes lymphangiogenesis, and a pharmaceutical preparation containing it |
| JPWO2023037868A1 (OSRAM) * | 2021-09-08 | 2023-03-16 | ||
| EP4249585A1 (en) * | 2022-03-25 | 2023-09-27 | Technische Universität München - TUM | Heart tissue models, method of producing heart tissue models and uses of heart tissue models |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003901668A0 (en) * | 2003-03-28 | 2003-05-01 | Medvet Science Pty. Ltd. | Non-haemopoietic precursor cells |
| JP2005524496A (ja) * | 2002-05-08 | 2005-08-18 | ザ リージェンツ オブ ザ ユニヴァーシティー オブ カリフォルニア | 非破壊性心伝導ブロック形成用システム及び方法 |
| JP2005538945A (ja) * | 2002-05-08 | 2005-12-22 | ザ リージェンツ オブ ザ ユニヴァーシティー オブ カリフォルニア | 心不整脈を線維芽細胞で治療するためのシステム及び方法 |
| US20040161412A1 (en) * | 2002-08-22 | 2004-08-19 | The Cleveland Clinic Foundation | Cell-based VEGF delivery |
| US7470538B2 (en) * | 2002-12-05 | 2008-12-30 | Case Western Reserve University | Cell-based therapies for ischemia |
| EP1689284A4 (en) * | 2003-11-10 | 2010-03-17 | Symphony Medical Inc | METHOD FOR REGULATING VENTRICULAR RHYTHM IN AURICULAR FIBRILLATION PATIENTS |
| US8513011B2 (en) * | 2004-08-26 | 2013-08-20 | Biotech Research Ventures Pte Limited | Methods and compositions for culturing cardiomyocyte-like cells |
| ES2325715B1 (es) * | 2007-08-03 | 2010-06-17 | Genetrix, S.L. | Poblacion de celulas madre adultas derivadas de tejido adiposo cardiaco y su uso en regeneracion cardiaca. |
| JP5378743B2 (ja) | 2008-09-30 | 2013-12-25 | テルモ株式会社 | 医療用細胞シートの製造方法 |
| US8802144B2 (en) * | 2011-08-25 | 2014-08-12 | Wisconsin Alumni Research Foundation | 3-dimensional cardiac fibroblast derived extracellular matrix |
| JP5920741B2 (ja) | 2012-03-15 | 2016-05-18 | ｉＨｅａｒｔ Ｊａｐａｎ株式会社 | 人工多能性幹細胞から心筋および血管系混合細胞群を製造する方法 |
| WO2014039995A1 (en) * | 2012-09-07 | 2014-03-13 | Fibrocell Technologies, Inc. | Fibroblast compositions for treating cardial damage after an infarct |
| GB201309057D0 (en) | 2013-05-20 | 2013-07-03 | Cell Therapy Ltd | Method |
| KR20150009655A (ko) * | 2013-07-16 | 2015-01-27 | 학교법인 동아학숙 | Gcp-2 유전자를 과발현하는 지방 간엽줄기세포를 포함하는 허혈성 질환 치료용 조성물 |
| CN106661552B (zh) * | 2014-07-11 | 2020-07-07 | 玛土撤拉有限公司 | 心脏细胞培养材料 |
-
2018
- 2018-02-23 JP JP2019501845A patent/JP6618066B2/ja active Active
- 2018-02-23 EP EP18758465.1A patent/EP3476395B1/en active Active
- 2018-02-23 WO PCT/JP2018/006795 patent/WO2018155651A1/ja not_active Ceased
- 2018-02-23 CN CN201880003050.1A patent/CN109890398B/zh active Active
- 2018-02-23 AU AU2018223739A patent/AU2018223739B2/en active Active
- 2018-02-23 DK DK18758465.1T patent/DK3476395T3/da active
- 2018-02-23 CA CA3032654A patent/CA3032654A1/en active Pending
- 2018-02-23 SG SG11201900810WA patent/SG11201900810WA/en unknown
- 2018-02-23 ES ES18758465T patent/ES2885080T3/es active Active
- 2018-02-23 KR KR1020197003364A patent/KR102407387B1/ko active Active
-
2019
- 2019-01-31 US US16/263,321 patent/US11096969B2/en active Active
- 2019-07-09 IL IL267958A patent/IL267958B2/en unknown
- 2019-10-03 JP JP2019182761A patent/JP7072135B2/ja active Active
-
2021
- 2021-07-19 US US17/379,671 patent/US20210346436A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019218408A (ja) | 2019-12-26 |
| CN109890398B (zh) | 2024-01-16 |
| EP3476395A4 (en) | 2020-02-26 |
| IL267958B1 (en) | 2023-04-01 |
| JPWO2018155651A1 (ja) | 2019-11-07 |
| KR20190117468A (ko) | 2019-10-16 |
| EP3476395A1 (en) | 2019-05-01 |
| EP3476395B1 (en) | 2021-07-21 |
| JP6618066B2 (ja) | 2019-12-11 |
| SG11201900810WA (en) | 2019-02-27 |
| AU2018223739A1 (en) | 2019-02-14 |
| US11096969B2 (en) | 2021-08-24 |
| CN109890398A (zh) | 2019-06-14 |
| ES2885080T3 (es) | 2021-12-13 |
| US20190224250A1 (en) | 2019-07-25 |
| IL267958B2 (en) | 2023-08-01 |
| AU2018223739B2 (en) | 2023-06-22 |
| KR102407387B1 (ko) | 2022-06-10 |
| US20210346436A1 (en) | 2021-11-11 |
| DK3476395T3 (da) | 2021-08-16 |
| JP7072135B2 (ja) | 2022-05-20 |
| IL267958A (en) | 2019-09-26 |
| WO2018155651A1 (ja) | 2018-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11096969B2 (en) | Composition for injection which can be used for treatment of heart diseases and contains fibroblasts, and method for producing fibroblast for therapy use | |
| Bao et al. | C-Kit Positive cardiac stem cells and bone marrow–derived mesenchymal stem cells synergistically enhance angiogenesis and improve cardiac function after myocardial infarction in a paracrine manner | |
| US20210145893A1 (en) | Compositions to amplify cardiac stem cells in vitro and in viv | |
| JP6883904B2 (ja) | 線維芽細胞の製造方法及びｇ−ｃｓｆ陽性線維芽細胞集団 | |
| US20200085875A1 (en) | Platelet vesicle-engineered cells for targeted tissue repair | |
| CN107257687A (zh) | 用于治疗心力衰竭的方法 | |
| US20160346331A1 (en) | Cardiac tissue-derived cells | |
| Fatkhudinov et al. | Bone Marrow‐Derived Multipotent Stromal Cells Promote Myocardial Fibrosis and Reverse Remodeling of the Left Ventricle | |
| CN106701668B (zh) | 间质干细胞、其纯株化扩张的方法及其应用 | |
| EP2205251B1 (en) | A method to amplify cardiac stem cells in vitro and in vivo | |
| US20210322484A1 (en) | Macromolecular clusters of cardiac stem cells and methods for making and using them | |
| WO2024176514A1 (ja) | 心臓内幹細胞を含む細胞集団 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230201 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20240816 |
|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE Effective date: 20241009 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250102 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250121 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250121 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250121 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250412 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250412 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250512 |
|
| R14 | Transfer of ownership recorded |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250517 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251021 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251022 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260427 |